ProMab Biotechnologies, Inc.
2600 Hilltop Drive
Building B, Suite C320
7 articles with ProMab Biotechnologies, Inc.
ProMab Biotechnology, Inc., a leading developer of CAR-T/NK cell technology for global life sciences, announced today it has successfully completed an investigator initiated trail (IIT) for CAR-T cell therapy. The study was conducted at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology by Prof. Hu Yu and Prof. Mei Heng in collaboration with Wuhan Sian Medical Technology using ProMab’s
NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate for Multiple Myeloma, with an Option for up to Five Additional CAR Targeting Sequences
ACEA Biosciences, a biotechnology company that develops high performance cell analysis instruments, hosted their 6th annual Cancer Immunotherapy Symposium focused on CAR-T cell and TCR therapy on April 14, 2018 at the W Hotel in Chicago, prior to the 2018 AACR Annual Meeting.
Helix Biopharma Announces The Signing Of A Non-Binding Letter Of Intent With ProMab Biotechnologies, Inc. To Develop Cell Based Therapies
ProMab Biotechnologies, Inc. a Corporate Support Sponsor for the San Francisco Molecular Med Tri-Con 2013